Therapeutic effectiveness against MOPC-315 plasmacytoma of low or high doses of the synthetic thymic hormone THF-gamma 2 in combination with an "immunomodulating" or a "non-immunomodulating" drug.
We reported previously that treatment of mice bearing MOPC-315 plasmacytoma with the drugs L-PAM (phenylalanine mustard) or 5-FU (5-fluorouracil), in combination with low doses of THF-gamma 2, was more effective in increasing their survival time than treatment with the drug alone. We show here that in the combined treatment using a single injection of 5-FU followed by multiple (8-15) injections of THF-gamma 2, the megadoses were more effective than the low doses in increasing the survival time of MOPC-315 tumor-bearing mice. On the other hand, in combination with L-PAM, both low and high doses of THF-gamma 2 were equally effective. The need for high doses of THF-gamma 2, when used in combination with 5-FU, could be due to the fact that 5-FU acts as a "non-immunomodulating" drug and has to be used at a high, immunosuppressive dose.
Ophir
R
R
Department of Human Microbiology, Sackler School of Medicine, Tel-Aviv University, Israel.
Pecht
M
M
Burstein
Y
Y
Harshemesh
H
H
Ben-Efraim
S
S
Trainin
N
N
D000818:Animals; D002460:Cell Line; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D005472:Fluorouracil / Q000627:therapeutic use*; D007167:Immunotherapy; D008558:Melphalan / Q000627:therapeutic use*; D051379:Mice; D008807:Mice, Inbred BALB C; D009842:Oligopeptides / Q000008:administration & dosage / Q000138:chemical synthesis / Q000627:therapeutic use*; D010954:Plasmacytoma / Q000188:drug therapy / Q000628:therapy*; D013951:Thymus Hormones / Q000627:therapeutic use*
D009842:Oligopeptides; D013951:Thymus Hormones; C064563:thymic humoral factor gamma 2; D008558:Melphalan; D005472:Fluorouracil